Adaptive Biotechnologies

Adaptive Biotechnologies Corporation is a commercial-stage company based in Seattle, Washington, that focuses on immune-driven medicine to enhance the diagnosis and treatment of various diseases. Founded in 2009, the company develops an immune medicine platform that includes the clonoSEQ diagnostic test, which is FDA-authorized for detecting and monitoring minimal residual disease in specific blood cancers, such as multiple myeloma and B cell acute lymphoblastic leukemia. In addition to clonoSEQ, Adaptive Biotechnologies offers immunoSEQ, a research service and kit that aids in discovering prognostic and diagnostic signals. The company also has a pipeline of clinical products aimed at addressing cancer, autoimmune conditions, and infectious diseases. Strategic collaborations with organizations like Genentech, Microsoft, and Amgen enhance its capabilities in developing innovative therapies and diagnostic tests.